Contribute Try STAT+ Today

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch …

Drug makers are crafting Covid-19 vaccines that would target more than one strain of the virus, hoping to strengthen the immunization campaign against the pathogen as it evolves, The Wall Street Journal writes. Researchers at Moderna (MRNA) and Novavax (NVAX) and the University of Oxford are designing the shots, known as multivalent vaccines, to protect not only against the form of the virus commonly circulating globally but also potentially contagious strains that have emerged or might in the future.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.